{"prompt": "['Alliance A221504', '13.7', 'Inclusion of Women and Minorities', 'This study will be available to all eligible patients, regardless of race, gender, or ethnic origin.', 'There is no information currently available regarding differential effects of these regimens in', 'subsets defined by race, gender, or ethnicity; and there is no reason to expect such differences', 'to exist. Therefore, although the planned analysis will, as always, look for differences in', 'treatment effect based on racial and gender groupings, the sample size is not increased in order', 'to provide additional power for such subset analyses.', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Not Hispanic or', 'Racial Categories', 'Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/ Alaska Native', 'Asian', 'Native Hawaiian or Other Pacific', 'Islander', 'Black or African American', '11', '16', '29', 'White', '69', '98', '4', '6', '177', 'More Than One Race', 'Total', '80', '114', '4', '6', '204', 'Ethnic', 'Hispanic or Latino - a person of Cuban, Mexican, Puerto Rican, South or Central', 'Categories:', 'American, or other Spanish culture or origin, regardless of race. The term \"Spanish', 'origin\" can also be used in addition to \"Hispanic or Latino.\"', 'Not Hispanic or Latino', 'Racial', 'American Indian or Alaskan Native - a person having origins in any of the original', 'Categories:', 'peoples of North, Central, or South America, and who maintains tribal affiliations or', 'community attachment.', 'Asian - a person having origins in any of the original peoples of the Far East, Southeast', 'Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan,', 'Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (Note:', 'Individuals from the Philippine Islands have been recorded as Pacific Islanders in', 'previous data collection strategies.)', 'Black or African American - a person having origins in any of the black racial groups', 'of Africa. Terms such as \"Haitian\" or \"Negro\" can be used in addition to \"Black or', 'African American.\"', 'Native Hawaiian or other Pacific Islander - a person having origins in any of the', 'original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.', 'White - a person having origins in any of the original peoples of Europe, the Middle', 'East, or North Africa.', '50', 'Update 2', 'Version Date 6/25/2019']['Alliance A221504', '14.0 CORRELATIVE AND COMPANION STUDIES', 'There will be 1 substudy and all patients are encouraged to participate.', '14.1 Biological mechanism of action, and biomarkers that would predict response/risk to the', 'study drug', '14.1.1 Background', 'Biological end-points based on our hypothesis will be evaluated in tumor biopsies and', 'plasma, pre-treatment and plasma post-treatment. For practical reasons, obtaining post-', 'treatment biopsies may not be feasible in this multi-center study. The hypothesis to be', 'addressed is that high mu opioid receptors (MOR) in the tumors co-activates receptor', 'tyrosine kinases for vascular endothelial growth factor receptor (VEGFR)-2 (on', 'endothelium) and epidermal growth factor receptor (EGFR) on the tumor cells and', 'downstream signaling pathways of mitogen activated protein kinase (MAPK/ERK) and', 'protein kinase B (PKB/Akt) that promote cell proliferation and survival, respectively, and', 'cyclo-oxygenase (COX)-2 signaling, leading to tumor progression and impairment of', 'HRQoL. We anticipate that tumors with higher mu opioid receptor expression will show', 'more responsiveness to naloxegol treatment and/or tumors with lower mu opioid receptor', 'expression may show slower growth on their own. Thus, tumors with higher mu opioid', 'receptors will show a correlative increase in the phosphorylation of endothelial VEGFR2,', 'EGFR on endothelial/tumor cells, MAPK/ERK and Akt, Stat3 and increased COX-', '2/prostaglandin (PG)-E2 in association with higher cell proliferation (by proliferating cell', 'nuclear antigen: PCNA) and cell survival (TUNEL staining) indices. Pain can influence pro-', 'inflammatory and vasoactive neuropeptide substance P (SP), which can promote tumor', 'growth-specific effects such as vascular permeability and angiogenesis, which may be', 'higher in patients with more pain in association with beta-endorphin, the endogenous ligand', 'for MOR. The levels of beta-endorphin and substance SP in the plasma will therefore', 'correlate with increased MOR in the tumor and with pain. In addition, since opioid receptors', 'can also modulate angiogenesis and lymphangiogenesis, these would correlate with MOR', 'and opioid use and beta-endorphin levels.', '14.1.2 Objectives', 'The main objective of the correlative science studies is to examine if MOR expression or', 'activation is a prognostic marker in advanced NSCLC, and whether its expression/activation', 'can be used to guide pain management. To examine this, the correlative studies will examine', 'if any potential beneficial effect of selective peripheral MOR inhibition by naloxegol on', 'HRQoL is limited to, or greater in, patients:', 'Whose tumors demonstrate a higher level of MOR expression/activation', 'With higher circulating levels of endogenous opioids, or', 'Those requiring higher doses (>5 mg/day average oral morphine equivalents', '[OME]) of pharmacological opioids', \"We will assess the mechanism of the study drug's impact by analyzing whether the HRQoL\", 'differences between the arms are greatest: 1) in patients with higher than the median MOR', 'expression on their tumors; 2) in those with higher than the median circulating endogenous', 'opioids; and 3) in those taking > 5 mg/day average oral morphine at the start of the trial.', 'If our hypothesis proves to be true, this line of investigation can be further advanced in', 'future studies to use fresh biopsies for isolating tumor cells and endothelial cells for', 'mechanism based studies and can also be used in organ culture to determine the therapeutic', 'potential of naloxegol on a case by case basis.', '51', 'Update 2', 'Version Date 6/25/2019']\n\n###\n\n", "completion": "END"}